| 投资者关系活动类别 | ☑特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | ☑现场参观 | | | □其他 | | | 永安国富 2 人 | | 活动参与人员 | 桂林三金董秘 李春 | | | 桂林三金证代 朱烨 | | 时间 | 2025 年 06 月 12 日 | | 地点 | 会议室 | | 形式 | 线下交流 1、未来公司销售费用投入以及销售费用率是否会有变化？ | | | 从近年的销售费用率来看，公司对销售费用投放使用把 控较为严格，呈现出愈加精准化，有侧重的投放趋势。目 | | | 前，公司的一线品种销售费用率会相对较低，销售费用的 | | | 投放使用重点向二、三线品种倾斜，并根据产品的销售进 | | | 度和市场变化做出相应调整，比如三金颗粒、舒咽清喷雾 | | | 剂等在培育阶段会给予较大的支持，一旦达到一定的体量 | | | 费用会有所调整。公司总体销售费用和公司的销售收入是 | | | 相互匹配的，全年的销售费用率不会有很大变化。 | | | 2、库存情况以及动销情况怎么样？ | | | ...

桂林三金药业股份有限公司投资者关系活动记录表 | 投资者关系活动类别 | □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | --- | --- | | | □新闻发布会 ☑路演活动 | | | □现场参观 | | | □其他 | | | 长江证券 2 人 | | 活动参与人员 | 桂林三金董秘 李春 | | | 桂林三金证代 朱烨 | | 时间 | 2025 年 06 月 06 日 | | 地点 | 会议室 | | 形式 | 线下交流 | | | 业绩情况简介： | | | 2024 年度公司实现营业总收入 219,399.20 万元，较 | | | 上年同期 217,160.34 万元增长 1.03%；实现利润总额 | | | 64,393.50 万元，较上年同期 51,828.39 万元增长 24.24%； | | | 实现归属于上市公司股东的净利润 52,153.36 万元，较上 | | | 年同期 42,129.88 万元增长 23.79%；2025 年第一季度实现 | | | 归属上市公司股东扣非净利润 9,767.29 万元，较上年同期 | | | 8,751.54 万元增长 11. ...

Financial Performance - In 2024, the company achieved total revenue of CNY 2,193.99 million, a growth of 1.03% compared to CNY 2,171.60 million in the previous year [1] - The total profit reached CNY 643.94 million, marking a 24.24% increase from CNY 518.28 million year-on-year [1] - Net profit attributable to shareholders was CNY 521.53 million, up 23.79% from CNY 421.30 million in the previous year [1] - In Q1 2025, the net profit after deducting non-recurring gains and losses was CNY 97.67 million, an increase of 11.61% from CNY 87.52 million in the same period last year [1] Business Strategy and Market Conditions - The biopharmaceutical sector is a key component of the company's dual-wing strategy, facing a challenging environment with high investment and long R&D cycles [1] - The industry is currently experiencing a downturn, with increased competition and diverse customer choices impacting business operations [1] - The company is focusing on cost control and optimizing employee structure to mitigate losses while continuing to invest in R&D [1] - Key projects, such as the BC006 monoclonal antibody injection, are progressing, with Phase I clinical trials nearing completion [1] Sales and Marketing Strategy - The company maintains strict control over sales expenses, with a focus on precision and targeted investment [2] - Sales expenses are being directed more towards second and third-tier products, with adjustments based on market performance [2] - The growth potential for second and third-tier products remains strong, with specific products like the Hagei Ding Chuan capsule expected to continue their growth trajectory [2] - The company aims to maintain a stable sales expense ratio in line with sales revenue [2] Dividend Policy - The company is committed to providing stable returns to investors, maintaining a consistent cash dividend policy since its listing [2] - For the 2024 fiscal year, the proposed dividend is CNY 3.5 per 10 shares, totaling CNY 206 million in cash dividends [2] - The company plans to continue its cash dividend strategy for the mid-2025 period, barring any special funding needs [2]

Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million yuan, a 1.03% increase from 2,171.60 million yuan in the previous year [1] - The total profit reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [1] - Net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% increase from 421.30 million yuan in the previous year [1] - In Q1 2025, the net profit attributable to shareholders after deducting non-recurring gains and losses was 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [1] Sales and Marketing Strategy - The company is focusing on a more precise allocation of sales expenses, with a trend towards targeted investments [1] - Sales expenses for frontline products are relatively low, with a shift towards supporting second and third-tier products based on sales progress and market changes [1] - Key products like Sanjin Granules and Shuyanqing Spray will receive significant support during their cultivation phase, with adjustments made once they reach a certain scale [1] Employee Incentives - The first employee stock ownership plan has successfully enhanced employee cohesion and competitiveness, and the company plans to refine this mechanism based on past experiences [2] - Other incentive methods will also be employed, including salary adjustments and corporate annuities, to motivate employees [2] Product Growth Potential - The company anticipates good growth for its second and third-tier products, with specific products like Hakeke Dinhua Capsules expected to maintain last year's growth rate [2] - The Xuanyun Ning series surpassed 100 million yuan in sales in 2021, with a goal of achieving double-digit growth this year [2] - Other products, such as Shuyanqing Spray and Compound Cold Medicine Granules, are also expected to maintain high growth rates [2] Dividend Policy - The company is committed to providing stable returns to investors and has consistently implemented a cash dividend policy since its listing [2] - For the 2024 annual equity distribution plan, the company proposes a cash dividend of 3.5 yuan per 10 shares, totaling 206 million yuan [2] - The dividend policy is expected to remain unchanged unless there are special funding needs [2]

Core Points - The company has approved a cash dividend distribution plan for the fiscal year 2024, which will be distributed at a rate of 3.50 RMB per 10 shares (including tax) [1][2] - The total number of shares for the dividend distribution is based on the existing total share capital of 587,568,600 shares, excluding any repurchased shares [1][2] - The dividend distribution date is set for May 29, 2025, with the ex-dividend date on May 30, 2025 [2][3] Dividend Distribution Details - The cash dividend of 3.50 RMB per 10 shares will be distributed to all shareholders, with different tax treatments for various types of investors [1][2] - For Hong Kong market investors and certain foreign institutions, the net dividend after tax will be 3.15 RMB per 10 shares [1][2] - The company will not withhold individual income tax at the time of distribution; tax will be calculated based on the holding period when shares are sold [2] Shareholder Information - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the close of trading on May 29, 2025 [2][3] - The distribution will be directly credited to the shareholders' accounts through their securities companies or other custodians [2][3] - The company assumes all legal responsibilities for any issues arising from insufficient cash dividends due to a decrease in shares held by shareholders during the distribution application period [2]

证券代码：002275 证券简称：桂林三金 公告编号：2025-021 桂林三金药业股份有限公司 2024年年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称 "公司"）2024 年年度利润分配方 案已获 2025 年 5 月 16 日召开的 2024 年度股东大会审议通过，现将分红派息事 宜公告如下： 一、股东大会审议通过利润分配方案等情况 1.2024 年年度利润分配方案已获 2025 年 5 月 16 日召开的 2024 年度股东大 会审议通过，具体方案为：以未来实施分配方案时股权登记日的总股本为基数， 向全体股东每 10 股派发现金股利 3.50 元（含税），不送红股，不以资本公积转 增股本。根据公司现有总股本 587,568,600 股为基数，预计共分配现金股利 205,649,010.00 元(含税)；如公司在实施权益分派的股权登记日前公司总股本 及应分配股数发生变动的，拟维持每股分配比例不变的原则，相应调整利润分配 总额。 2.公司回购专用证券账户中的股份不参与本次权益分派，截至目前，公司回 ...

Group 1 - The core revenue of the company primarily comes from traditional Chinese medicine, with contributions from chemical drugs and daily health products [1] - The company is focusing on expanding its sales channels for its watermelon frost toothpaste series, which includes various products and is currently being promoted in second-tier and lower cities [1] - The company plans to leverage its brand recognition and capital market advantages to strengthen its market position in daily health products [1] Group 2 - The overall development trend for the company's second and third-tier products is positive, with continued support for these products [2] - The company aims for double-digit growth in the sales of the dizziness relief series, which surpassed 100 million yuan in sales in 2021 [2] - The losses from the large pharmacy chain are attributed to significant expansion costs, and the chain is currently focused on the Guilin area to enhance the company's marketing strategy and sales channels [2]

Group 1: Company Overview - Guilin Sanjin Pharmaceutical Co., Ltd. is listed under stock code 002275 and is known for its focus on traditional Chinese medicine and health products [1]. Group 2: Financial Performance - The company plans to distribute a cash dividend of 3.5 CNY per 10 shares, totaling 206 million CNY for the 2024 fiscal year [3]. - The company has maintained a consistent cash dividend policy since its listing, ensuring stable cash flow for operations and development [3]. Group 3: Sales Composition - The majority of sales revenue comes from traditional Chinese medicine, with significant contributions from first-line products like Sanjin Pian and Xigua Frost series [3]. - Second-line products, such as Zhuan Yun Ning and He Qie Ding Chuan capsules, are expected to see growth, while third-line products are still in the market development phase [3]. Group 4: Business Strategy - The company is expanding its retail pharmacy operations, which faced losses due to high expansion costs, but is seen as a crucial part of the marketing strategy [2]. - The company is investing in the development of its personal care products, including Xigua Frost toothpaste, with a focus on expanding sales channels [3]. Group 5: R&D and Future Prospects - The company is actively pursuing new drug research and development, with ongoing projects expected to yield significant results [4]. - The second and third-line products are projected to have a positive growth trend, with specific targets set for various products to achieve substantial sales milestones [4].

中国北京市建国门外大街 1 号国贸写字楼 2 座 12 -15 层 100004 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于桂林三金药业股份有限公司 二、 本次股东大会出席人员的资格、召集人的资格 根据现场会议的统计结果以及网络投票系统的提供机构深圳证券信息有限 公司提供的网络投票结果，出席本次股东大会的股东及股东代表共计 82 人，代 表股份 417,031,460 股，占公司有表决权股份总数的 70.9758%。其中：出席现场 会议的股东及股东代表 15 人，代表股份 412,512,257 股，占公司有表决权股份总 数的 70.2067%。通过网络投票的股东 67 人，代表股份 4,519,203 股，占公司有 表决权股份总数的 0.7691%。 其中，出席本次会议的中小股东（除董事、监事、高级管理人员及单独或者 合计持有公司 5%以上股份以外的股东）76 人，代表股份 14,315,780 股，占公司 有 ...

一、 本次股东大会的召集与召开程序 本次股东大会由公司第八届董事会第十三次会议决议召集。公司于 2025 年 4 月 26 日在《中国证券报》《证券时报》《证券日报》及巨潮资讯网 （www.cninfo.com.cn）上公告了《关于召开 2024 年度股东大会的通知》（以下 简称"会议通知"），会议通知载明了本次股东大会的召开时间和地点、投票方 式、会议召开方式、股权登记日、出席人员、会议审议事项和提案、会议登记相 关事项等内容。 本次股东大会采取现场表决和网络投票相结合的表决方式。本次股东大会现 场会议于 2025 年 5 月 16 日 14:30 在广西桂林市临桂区人民南路 9 号公司四楼会 议室如期举行。网络投票时间为：（1）通过深圳证券交易所交易系统进行网络 投票的具体时间为：2025 年 5 月 16 日 9:15-9:25，9:30-11:30 和 13:00-15:00；（2） 通过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 5 月 16 日 9:15-15:00 期间的任意时间。 关于桂林三金药业股份有限公司 2024 年 ...